



Date: 10th November, 2025

To,
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Scrip Code: 539730

Dear Sir/ Madam,

Sub.: Press Release Issued by Fredun Pharmaceuticals Limited

Please find enclosed press release titled “**Fredun Pharmaceuticals Reports 61% YoY Growth in EBITDA to ₹39.33 Cr in H1 FY26**” issued by Fredun Pharmaceuticals Limited.

Thanking you,

Yours truly,

For Fredun Pharmaceuticals Limited

Fredun Nariman Medhora
Managing Director
DIN: 01745348





Fredun Pharmaceuticals Reports 61% YoY Growth in EBITDA to ₹39.33 Cr in H1 FY26

Mumbai – November 08, 2025: – Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and animal healthcare products, has reported its Unaudited financials for Q2 FY26 & H1 FY26.

Key Financial Highlights

Particulars (₹ Cr)	Standalone			Standalone		
	Q2 FY26	Q2 FY25	YoY	H1 FY26	H1 FY25	YoY
Total Income	145.29	107.35	↑ 35.34%	265.15	186.16	↑ 42.43%
EBITDA	22.34	13.95	↑ 60.09%	39.33	24.43	↑ 60.98%
EBITDA Margin (%)	15.37	13.00	↑ 238 Bps	14.83	13.12	↑ 171 Bps
Net Profit	9.73	4.27	↑ 127.75%	16.50	8.40	↑ 96.33%
Net Profit margin (%)	6.70	3.98	↑ 272 Bps	6.22	4.51	↑ 171 Bps
EPS (₹)	20.61	9.05	↑ 127.73%	34.94	17.80	↑ 96.29%

Commenting on the financial performance Mr. Fredun Medhora, Managing Director, said, “Q2 FY26 was a strong quarter for Fredun, driven by consistent growth across our pharmaceutical and pet care verticals. Our domestic formulations segment continued to deliver solid performance through new product introductions and expanding institutional demand, while exports maintained steady traction. We have commenced expansion of our state-of-the-art manufacturing facility at Palghar to enhance capacity, improve operational efficiency, and support the growing demand across both domestic and international markets.

The past few months have been pivotal in shaping Fredun’s position as a first mover in India’s organized pet healthcare space. The launch of Snacky Jain—India’s first Jain functional food for pets—received an overwhelming response, with the entire first batch sold out through pre-orders. Backed by robust capacity, strong retail partnerships, and growing presence across eight states, this launch reinforces our ethical and research-led approach to pet nutrition. Our acquisitions of Wagrai and One Pet Stop have expanded our footprint across nutrition, technology, and services—creating a truly connected and science-driven pet care ecosystem. This integrated approach positions us uniquely at the intersection of healthcare, nutrition, and technology in a market poised for exponential growth. We reported improved cash flows this quarter, driven by efficient execution and disciplined operations.

Looking ahead, we aim to scale our operations, accelerate new product launches, and strengthen our digital-first platforms to enhance accessibility and experience for pet parents. With a clear strategy, strong execution, and first-mover advantage, we remain confident of sustaining our growth momentum and building long-term value for all”

Key Business Highlights

Preferential Issue of Securities	<ul style="list-style-type: none"> • Type: Equity Shares (6,52,360) and Convertible Warrants (5,73,600) • Face Value: Rs. 10 per Equity Share/Warrant • Issue Price: Rs. 1,250 per Equity Share/Warrant
Declaration of Final Dividend	<ul style="list-style-type: none"> • Dividend Rate: 7% on equity shares • Face Value: ₹10 per share
Strategic Acquisitions	<ul style="list-style-type: none"> • Wagr.ai: A leading pet-tech platform offering an AI-driven ecosystem for pet products & services. • One Pet Stop Pvt. Ltd: A pet grooming and wellness services provider offering tech-enabled doorstep grooming.
New Product Launch	<ul style="list-style-type: none"> • Snacky Jain: India's first 100% Jain-compliant functional food for pets, made with natural, plant-based ingredients to support overall pet health and wellness

About Fredun Pharmaceuticals Limited


Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor

	Kirin Advisors Private Limited Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com
---	---